Dengue

British Medical Bulletin

Volumn 95, Issue 1, 2010, Pages 161-173

  Whitehorn, James ^a   Farrar, Jeremy ^b  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

Author keywords

dengue; dengue haemorrhagic fever; dengue shock syndrome; drug development; pathogenesis; vaccine

Indexed keywords

DENGUE VACCINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; NONSTRUCTURAL PROTEIN 1; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 5;

AEDES AEGYPTI; CLINICAL FEATURE; DENGUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUID THERAPY; HUMAN; IMMUNOGENICITY; IMMUNOPATHOGENESIS; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; NONHUMAN; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; VACCINE PRODUCTION; VECTOR CONTROL; VIRUS TRANSMISSION; VIRUS VIRULENCE; WORLD HEALTH ORGANIZATION;

EID: 77956256470     PISSN: 00071420     EISSN: 14718391     Source Type: Journal    
DOI: 10.1093/bmb/ldq019     Document Type: Review

References (94)

1. Halstead SB. Dengue. Lancet 2007;370:1644-1652
2. Halstead SB. Pathogenesis of dengue: challenges to molecular biology. Science 1988;239:476-481
3. Webster DP, Farrar J, Rowland-Jones S. Progress towards a dengue vaccine. Lancet Infect Dis 2009;9:678-687
4. DengueNet-WHOs Internet-based system for the global surveillance of dengue fever and dengue haemorrhagic fever (dengue/DHF). Dengue/DHF-global public health burden. Wkly Epidemiol Rec 2002;77:300-304 http://www.who.int/ denguenet.
5. Franco L, Caro AD, Carletti F et al. Recent expansion of dengue virus serotype 3 in West Africa. Euro Surveill 2010;15:19490.
6. Gubler DJ. The changing epidemiology of yellow fever and dengue, 1900 to 2003: full circle? Comp Immunol Microbiol Infect Dis 2004;27:319-330
7. Hsieh YH, Chen CW. Turning points, reproduction number, and impact of climatological events for multi-wave dengue outbreaks. Trop Med Int Health 2009;14:628-638
8. Gubler DJ. Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol 2002;10:100-103
9. Gubler DJ. Cities spawn epidemic dengue viruses. Nat Med 2004;10:129-130
10. Anuradha S, Singh NP, Rizvi SN et al. The 1996 outbreak of dengue hemorrhagic fever in Delhi, India. Southeast Asian J Trop Med Public Health 1998;29:503-506
11. Vaughn DW. Invited commentary: dengue lessons from Cuba. Am J Epidemiol 2000;152:800-803
12. Clark DV, Mammen MP Jr, Nisalak A et al. Economic impact of dengue fever/dengue hemorrhagic fever in Thailand at the family and population levels. Am J Trop Med Hyg 2005;72:786-791
13. Luz PM, Grinsztejn B, Galvani AP. Disability adjusted life years lost to dengue in Brazil. Trop Med Int Health 2009;14:237-246
14. Farrar J, Focks D, Gubler D et al. Towards a global dengue research agenda. Trop Med Int Health 2007;12:695-699
15. Allwinn R, Hofknecht N, Doerr HW. Dengue in travellers is still underestimated. Intervirology 2008;51:96-100.
16. WHO. Dengue haemorrhagic fever: diagnosis, treatment, prevention and control. 2nd Edition Geneva: World Health Organisation, 1997, ed.
17. WHO. In Asia ROfS-E (eds) Guidelines for treatment of dengue fever/dengue haemorrhagic fever in small hospitals. New Delhi: World Health Organisation, 1999, editor.
18. Kalayanarooj S, Vaughn DW, Nimmannitya S et al. Early clinical and laboratory indicators of acute dengue illness. J Infect Dis 1997;176:313-321
19. Deen JL, Harris E, Wills B et al. The WHO dengue classification and case definitions: time for a reassessment. Lancet 2006;368:170-173
20. Endy TP, Chunsuttiwat S, Nisalak A et al. Epidemiology of inapparent and symptomatic acute dengue virus infection: a prospective study of primary school children in Kamphaeng Phet, Thailand. Am J Epidemiol 2002;156:40-51.
21. Kabra SK, Jain Y, Singhal T et al. Dengue hemorrhagic fever: clinical manifestations and management. Indian J Pediatr 1999;66:93-101.
22. McBride JH. Dengue fever. An Australian perspective. Aust Fam Physician 1999;28:319-323
23. tsai CJ, Kuo CH, Chen PC et al. Upper gastrointestinal bleeding in dengue fever. Am J Gastroenterol 1991;86:33-35
24. thisyakorn U, Thisyakorn C. Dengue infection with unusual manifestations. J Med Assoc Thai 1994;77:410-413
25. Wang C, Lee I, Su M et al. Differences in clinical and laboratory characteristics and disease severity between children and adults with dengue virus infection in Taiwan, 2002. Trans R Soc Trop Med Hyg 2009;103:871-877
26. Seet RC, Quek AM, Lim EC. Post-infectious fatigue syndrome in dengue infection. J Clin Virol 2007;38:1-6.
27. Chye JK, Lim CT, Ng KB et al. Vertical transmission of dengue. Clin Infect Dis 1997;25:1374-1377
28. WHO. Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control, new edn. Geneva: World Health Organisation, 2009.
29. Kliks SC, Nisalak A, Brandt WE et al. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am J Trop Med Hyg 1989;40:444-451
30. Halstead SB. Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res 2003;60:421-467
31. Martina BE, Koraka P, Osterhaus AD. Dengue virus pathogenesis: an integrated view. Clin Microbiol Rev 2009;22:564-581
32. Leitmeyer K, Vaughn D, Watts D et al. Dengue virus structural differences that correlate with pathogenesis. J Virol 1999;73:4738-4747
33. Sanchez I, Ruiz B. A single nucleotide change in the E protein gene of dengue virus 2 Mexican strain affects neurovirulence in mice. J Gen Virol 1996;77:2541-2545
34. Streatfield R, Bielby G, Sinclair D. A primary dengue 2 epidemic with spontaneous haemorrhagic manifestations. Lancet 1993;342:560-561
35. Guzman MG, Kouri G, Halstead SB. Do escape mutants explain rapid increases in dengue case-fatality rates within epidemics? Lancet 2000;355:1902-1903
36. Vaughn DW, Green S, Kalayanarooj S et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 2000;181:2-9.
37. Diamond M, Edgil D, Roberts T et al. Infection of human cells by dengue virus is modulated by different cell types and viral strains. J Virol 2000;74:7814-7823
38. Kurane I, Innis BL, Nimmannitya S et al. Activation of T lymphocytes in dengue virus infections. High levels of soluble interleukin 2 receptor, soluble CD4, soluble CD8, interleukin 2, and interferon-gamma in sera of children with dengue. J Clin Invest 1991;88:1473-1480
39. Hober D, Poli L, Roblin B et al. Serum levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-1 beta (IL-1 beta) in dengue-infected patients. Am J Trop Med Hyg 1993;48:324-331
40. Fernandez-Mestre MT, Gendzekhadze K, Rivas-Vetencourt P et al. TNF-alpha-308A allele, a possible severity risk factor of hemorrhagic manifestation in dengue fever patients. Tissue Antigens 2004;64:469-472
41. Acioli-Santos B, Segat L, Dhalia R et al. MBL2 gene polymorphisms protect against development of thrombocytopenia associated with severe dengue phenotype. Hum Immunol 2008;69:122-128
42. LaFleur C, Granados J, Vargas-Alarcon G et al. HLA-DR antigen frequencies in Mexican patients with dengue virus infection: HLA-DR4 as a possible genetic resistance factor for dengue hemorrhagic fever. Hum Immunol 2002;63:1039-1044
43. Loke H, Bethell D, Phuong CX et al. Susceptibility to dengue hemorrhagic fever in Vietnam: evidence of an association with variation in the vitamin d receptor and Fc gamma receptor IIa genes. Am J Trop Med Hyg 2002;67:102-106
44. Loke H, Bethell DB, Phuong CX et al. Strong HLA class I-restricted T cell responses in dengue hemorrhagic fever: a double-edged sword? J Infect Dis 2001;184:1369-1373
45. Monath T, Barrett A. Pathogenesis and pathophysiology of yellow fever. Adv Virus Res 2003;60:343-395
46. Graham RR, Juffrie M, Tan R et al. A prospective seroepidemiologic study on dengue in children four to nine years of age in Yogyakarta, Indonesia I. Studies in 1995 -1996. Am J Trop Med Hyg 1999;61:412-419
47. Kalayanarooj S, Nimmannitya S. Clinical presentations of dengue hemorrhagic fever in infants compared to children. J Med Assoc Thai 2003;86:S673-80.
48. Chau TN, Quyen NT, Thuy TT et al. Dengue in Vietnamese infants-results of infection-enhancement assays correlate with age-related disease epidemiology, and cellular immune responses correlate with disease severity. J Infect Dis 2008;198:516-524
49. Guzman MG, Kouri G. Dengue: an update. Lancet Infect Dis 2002;2:33-42.
50. Wichmann O, Hongsiriwon S, Bowonwatanuwong C et al. Risk factors and clinical features associated with severe dengue infection in adults and children during the 2001 epidemic in Chonburi, Thailand. Trop Med Int Health 2004;9:1022-1029
51. Dejnirattisai W, Jumnainsong A, Onsirisakul N et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science 2010;328:745-748
52. Chau T, Anders K, Lien lB et al. Clinical and virological features of dengue in Vietnamese infants. PLoS Negl Trop Dis 2010;4:e657.
53. Stephenson JR. Understanding dengue pathogenesis: implications for vaccine design. Bull World Health Organ 2005;83:308-314
54. Hang VT, Nguyet NM, Trung DT et al. Diagnostic accuracy of NS1 ELISA and lateral flow rapid tests for dengue sensitivity, specificity and relationship to viraemia and antibody responses. PLoS Negl Trop Dis 2009;3:e360.
55. Avirutnan P, Punyadee N, Noisakran S et al. Vascular leakage in severe dengue virus infections: a potential role for the nonstructural viral protein NS1 and complement. J Infect Dis 2006;193:1078-1088
56. Rico-Hesse R. Dengue virus markers of virulence and pathogenicity. Future Virol 2009;4:581.
57. Srikiathachorn A, Gibbons R, Green S et al. Dengue haemorrhagic fever: the sensitivity and specificity of the World Health Organisation definitions for identification of severe cases of dengue in Thailand, 1994-2005. Clin Infect Dis 2010;50:1135-1143
58. Kalayanarooj S. Standardised clinical management: evidence of reduction of dengue haemorrhagic fever case-fatality rate in Thailand. Dengue Bull 1999;23:10-17
59. Sumarmo, Wulur H, Jahja E et al. Clinical observations on virologically confirmed fatal dengue infections in Jakarta, Indonesia. Bull World Health Organ 1983;61:693-701.
60. Phuong CX, Nhan NT, Kneen R et al. Clinical diagnosis and assessment of severity of confirmed dengue infections in Vietnamese children: is the world health organization classification system helpful? Am J Trop Med Hyg 2004;70:172-179
61. Harris E, Videa E, Perez L et al. Clinical, epidemiologic, and virologic features of dengue in the 1998 epidemic in Nicaragua. Am J Trop Med Hyg 2000;63:5-11.
62. Teixeira MG, Costa Mda C, Barreto F et al. Dengue: twenty-five years since reemergence in Brazil. Cad Saude Publica 2009;25:S7-18.
63. Moxon C, Wills B. Management of severe dengue in children. Adv Exp Med Biol 2008;609:131-144
64. Wills BA, Nguyen MD, Ha TL et al. Comparison of three fluid solutions for resuscitation in dengue shock syndrome. N Engl J Med 2005;353:877-889
65. Hunsperger EA, Yoksan S, Buchy P et al. Evaluation of commercially available anti-dengue virus immunoglobulin M tests. Emerg Infect Dis 2009;15:436-440
66. Libraty DH, Young PR, Pickering D et al. High circulating levels of the dengue virus non- structural protein NS1 early in dengue illness correlate with the development of dengue hemorrhagic fever. J Infect Dis 2002;186:1165-1168
67. Kong YY, Thay CH, Tin TC et al. Rapid detection, serotyping and quantitation of dengue viruses by TaqMan real-time one-step RT-PCR. J Virol Methods 2006;138:123-130
68. Tanner L, Schreiber M, Low JG et al. Decision tree algorithms predict the diagnosis and outcome of dengue fever in the early phase of illness. PLoS Negl Trop Dis 2008;2:e196.
69. Srikiatkhachorn A, Krautrachue A, Ratanaprakarn W et al. Natural history of plasma leakage in dengue hemorrhagic fever: a serial ultrasonographic study. Pediatr Infect Dis J 2007;26:283-90; discussion 91-92
70. Srikiatkhachorn A, Green S. Markers of dengue disease severity. Curr Top Microbiol Immunol 2010;338:67-82.
71. Edelman R. Dengue vaccines approach the finish line. Clin Infect Dis 2007;45:S56 -60.
72. Innis BL, Eckels KH. Progress in development of a live-attenuated, tetravalent dengue virus vaccine by the United States Army Medical Research and Materiel Command. Am J Trop Med Hyg 2003;69:1-4.
73. Edelman R, Wasserman SS, Bodison SA et al. Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am J Trop Med Hyg 2003;69:48-60.
74. Sun W, Edelman R, Kanesa-Thasan N et al. Vaccination of human volunteers with mono- valent and tetravalent live-attenuated dengue vaccine candidates. Am J Trop Med Hyg 2003;69:24-31.
75. Halstead SB, Marchette NJ. Biologic properties of dengue viruses following serial passage in primary dog kidney cells: studies at the University of Hawaii. Am J Trop Med Hyg 2003;69:5-11.
76. Guirakhoo F, Kitchener S, Morrison D et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccin 2006;2:60-67
77. Guirakhoo F, Pugachev K, Zhang Z et al. Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J Virol 2004;78:4761-4775
78. Castilow E, Olson M, Varga S. Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease. Immunol Res 2007;39:225-239
79. Edelman R, Hombach J. "Guidelines for the clinical evaluation of dengue vaccines in endemic areas": summary of a World Health Organisation Technical Consultation. Vaccine 2008;26:4113-4119
80. Swaminathan S, Khanna N. Dengue: recent advances in biology and current status of translational research. Curr Mol Med 2009;9:152-173
81. Heinz F, Allison S. The machinery for flavivirus fusion with host cell membranes. Curr Opin Microbiol 2001;4:450-455
82. Wang Q, Patel S, Vangrevelinghe E et al. A small-molecule dengue virus inhibitor. Antimicrob Agents Chemother 2009;53:1823-1831
83. Lescar J, Luo D, Xu T et al. Towards the design of antiviral inhibitors against flaviviruses: the case for the multifunctional NS3 protein from Dengue virus as a target. Antiviral Res 2008;80:94-101.
84. Melino S, Paci M. Progress for dengue virus diseases. Towards the NS2B-NS3pro inhibition for a therapeutic-based approach. FEBS J 2007;274:2986-3002.
85. Tomlinson SM, Malmstrom RD, Watowich SJ. New approaches to structure-based discovery of dengue protease inhibitors. Infect Disord Drug Targets 2009;9:327-343
86. Webster D, Klenerman P, Collier J et al. Development of novel treatments for hepatitis C. Lancet Infect Dis 2009;9:108-117
87. Chung K, Nybakken G, Thompson B et al. Antibodies against West Nile Virus nonstructural protein NS1 prevent lethal infection through Fc gamma receptor-dependent and -independent mechanisms. J Virol 2006;80:1340-1351
88. Shrestha B, Brien J, Sukupolvi-Petty S et al. The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog 2010;6:e1000823.
89. Ooi EE, Goh KT, Gubler DJ. Dengue prevention and 35 years of vector control in Singapore. Emerg Infect Dis 2006;12:887-893
90. Gubler DJ, Nalim S, Tan R et al. Variation in susceptibility to oral infection with dengue viruses among geographic strains of Aedes aegypti. Am J Trop Med Hyg 1979;28:1045-1052
91. Hanley K, Nelson J, Schirtzinger E et al. Superior infectivity for mosquito vectors contributes to competitive displacement among strains of dengue virus. BMC Ecol 2008;8:1.
92. Medlock J, Luz PM, Struchiner CJ et al. The impact of transgenic mosquitoes on dengue virulence to humans and mosquitoes. Am Nat 2009;174:565-577
93. Rasgon J. Using predictive models to optimize Wolbachia-based strategies for vector-borne disease control. Adv Exp Med Biol 2008;627:114-125
94. Marten G, Reid J. Cyclopoid copepods. J Am Mosq Control Assoc 2007;23:65-92.